Cellectar Biosciences will present at the 37th Annual Roth Conference on March 17, 2025.
Quiver AI Summary
Cellectar Biosciences, Inc., a late-stage clinical biopharmaceutical company focused on developing cancer treatments, announced that its management team will present an overview of the company at the 37th Annual Roth Conference on March 17, 2025, at 8:30 AM ET, with a webcast available for viewers. The company is advancing its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to create targeted cancer therapies with improved efficacy and safety. Its product pipeline includes leading assets such as iopofosine I 131 for relapsed or refractory multiple myeloma and CNS lymphoma, as well as programs targeting solid tumors like pancreatic cancer and triple-negative breast cancer. Iopofosine I 131 has received multiple FDA designations, including Orphan Drug and Fast Track, and findings from ongoing trials may lead to significant pediatric applications. Further information can be found on the company’s website and social media.
Potential Positives
- Cellectar Biosciences will present an overview of the company at the 37th Annual Roth Conference, potentially increasing visibility among investors and stakeholders.
- The company has a diverse and promising product pipeline, including iopofosine I 131, which has received multiple FDA designations such as Orphan Drug and Fast Track Designations for various cancer indications.
- The company is focused on innovative drug delivery methods through its proprietary Phospholipid Drug Conjugate™ (PDC) platform, which aims to improve treatment efficacy and reduce side effects.
Potential Negatives
- The press release does not provide any recent updates or results from the company's clinical trials, which may raise concerns about the current status and progress of their drug development programs.
- The reliance on designations such as Orphan Drug and Fast Track may indicate the company is focusing on niche markets, which could limit overall market potential and revenue generation.
- No specifics on financial performance or funding status are provided, which could lead to questions about the company's financial health and ability to sustain operations and development initiatives.
FAQ
What is the date and time of the Cellectar Biosciences presentation?
The presentation will take place on March 17, 2025, at 8:30 AM Eastern Time.
Where can I find the webcast for the presentation?
The webcast link will be available on the Cellectar Biosciences corporate website prior to the event.
What is the focus of Cellectar Biosciences?
Cellectar Biosciences specializes in developing drugs for cancer treatment, utilizing their proprietary Phospholipid Drug Conjugate™ platform.
What are some of Cellectar's key drug candidates?
Cellectar's key drug candidates include iopofosine I 131, CLR 121225, and CLR 121125, targeting various cancers.
What FDA designations has iopofosine I 131 received?
iopofosine I 131 has received Orphan Drug, Rare Pediatric Drug, and Fast Track Designations from the FDA.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CLRB Hedge Fund Activity
We have seen 17 institutional investors add shares of $CLRB stock to their portfolio, and 22 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ROSALIND ADVISORS, INC. removed 3,671,550 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,097,793
- AIGH CAPITAL MANAGEMENT LLC removed 3,197,394 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $956,020
- NANTAHALA CAPITAL MANAGEMENT, LLC removed 2,712,443 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $811,020
- SQUAREPOINT OPS LLC added 520,240 shares (+inf%) to their portfolio in Q4 2024, for an estimated $155,551
- ADAR1 CAPITAL MANAGEMENT, LLC removed 436,900 shares (-42.7%) from their portfolio in Q4 2024, for an estimated $130,633
- UBS GROUP AG added 373,622 shares (+14498.3%) to their portfolio in Q4 2024, for an estimated $111,712
- ALTIUM CAPITAL MANAGEMENT LP added 215,000 shares (+inf%) to their portfolio in Q3 2024, for an estimated $460,100
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
FLORHAM PARK, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that members of its management team will present an overview of the company at the upcoming 37th Annual Roth Conference. Details are as follows:
Date: Monday, March 17
Time: 8:30 AM Eastern Time
Webcast:
Click HERE
A replay of the corporate presentation will be available on the Events section of the company’s Investor Relations website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes its lead assets: iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope); CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer; and CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
In addition, iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, and the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications.
For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter , LinkedIn , and Facebook .
Investor Contact:
Anne Marie Fields
Precision AQ
212-362-1200
[email protected]
